Cover of Venous access

Venous access

Neonatal parenteral nutrition

Evidence review B

NICE Guideline, No. 154

Authors

.

London: National Institute for Health and Care Excellence (NICE); .
ISBN-13: 978-1-4731-3673-1
Copyright © NICE 2020.

Venous access for parenteral nutrition in preterm and term babies

Review question

What overall osmolality (concentration of calcium and glucose/dextrose), in parenteral nutrition can determine whether to administer centrally or peripherally?

Introduction

Parenteral Nutrition (PN) is administered intravenously, and either peripheral or central venous lines can be used. Central lines are often inserted through the umbilical vessels in new-born infants; however, lines can also be inserted peripherally; they are used for drug infusions as well as PN.

Central lines are positioned in a large bore central vein. This allows infusion of more concentrated substances securely; and in general these lines are able to be left in situ for a longer period of time if carefully maintained. However, they require a greater degree of technical skill for insertion; and can be more prone to serious complications such as being a source of late onset sepsis. Peripheral lines are very commonly used for a number of indications on neonatal units and are generally easier to insert. They have a shorter life span. As the infusions are running into a smaller peripheral vein, there is greater risk of the infusion causing direct damage to the vein (thrombophlebitis) or leaking out into the surrounding tissues (extravasation). This is particularly true where there is a higher concentration (as measured by osmolality or osmolarity depending on the unit of measurement) of the PN infusion fluid, such as a formulation with a higher dextrose load.

Current practice varies with regards to the administration of PN centrally or peripherally, and this review aims to look at whether the osmolality or osmolarity of PN can help guide whether it is safe to administer peripherally or if PN should be administered centrally.

Summary of the protocol

Please see Table 1 for a summary of the Population, Intervention, Comparison and Outcome (PICO) characteristics of this review.

Table 1. Summary of the protocol (PICO table).

Table 1

Summary of the protocol (PICO table).

For full details see the review protocol in appendix A.

Clinical evidence

Included studies

No randomised controlled trials (RCTs) were identified; therefore, observational studies were included to inform decision making.

One observational study was identified for this review (Cies 2014).

This study compared a PN formulation with osmolarity > 900 mOsm/L to a PN formulation with osmolarity ≤ 900 mOsm/L in babies receiving peripherally inserted catheters (Cies 2014).

The included study is summarised in Table 2.

Table 2. Summary of included studies.

Table 2

Summary of included studies.

See the literature search strategy in appendix B, study selection flow chart in appendix C, study evidence tables in appendix D, and GRADE tables in appendix F.

Excluded studies

Studies not included in this review are listed, and reasons for their exclusions are provided in appendix K.

Summary of clinical studies included in the evidence review

A summary of the study included in this review is presented in Table 2.

See appendix D for full evidence tables.

Quality assessment of clinical outcomes included in the evidence review

GRADE was conducted to assess the quality of outcomes. Evidence was identified for critical outcomes; no important outcomes were selected by the committee. The clinical evidence profiles can be found in appendix F.

Economic evidence

Included studies

A systematic review of the economic literature was conducted but no economic studies were identified which were applicable to this review question. A single economic search was undertaken for all topics included in the scope of this guideline. Please see supplementary material D for details.

Excluded studies

No studies were identified which were applicable to this review question.

Summary of studies included in the economic evidence review

No economic evaluations were identified which were applicable to this review question.

Economic model

This topic was prioritised for economic modelling. However, no economic modelling was undertaken for this review because the clinical data were insufficient to inform the economic analysis.

Evidence statements

Clinical Evidence statements

Line related events per number of patient days of PN (grade 1–2)
  • Very low quality evidence from 1 observational study (n=236) showed no clinically important difference in babies receiving PN with osmolarity > 900 mOsm/L versus PN with osmolarity ≤ 900 mOsm/L: Relative risk (RR) 1.06 (95% CI 0.90, 1.24)
Line related events per number of patient days of PN (grade 3)
  • Very low quality evidence from 1 observational study (n=236) showed no clinically important difference (there were no events in either arm) in babies receiving PN with osmolarity > 900 mOsm/L versus PN with osmolarity ≤ 900 mOsm/L: Risk difference (RD) 0.00 (−0.01 to 0.01, 0 events in both groups).
Line related events per number of patient days of PN (grade 4)
  • Very low quality evidence from 1 observational study (n=236) showed a clinically important difference in the number of Grade 4 line related events in babies receiving PN with osmolarity > 900 mOsm/L as compared to those receiving PN with osmolarity ≤ 900 mOsm/L; with fewer events in those receiving PN with osmolality > 900 mOsm/L. However, there was high uncertainty around the effect: Peto odds ratio (POR) 0.24 (95% CI 0.00, 16.71)
Line related events per number of patient days of PN (all grades)
  • Very low quality evidence from 1 observational study (n=236) showed no clinically important difference in babies receiving PN with osmolarity > 900 mOsm/L versus PN with osmolarity ≤ 900 mOsm/L. However, there was uncertainty around the effect: RR 1.06 (95% CI 0.90, 1.24)
Rate of line related events per 100 patient days of PN (<32 weeks’ GA)
  • Very low quality evidence from 1 observational study (n=236) showed no clinically important difference in babies receiving PN with osmolarity > 900 mOsm/L versus PN with osmolarity ≤ 900 mOsm/L. However, there was uncertainty around the effect: RR 1.07 (95% CI 0.80, 1.43)
Rate of line related events per 100 patient days of PN (32–37 weeks’ GA)
  • Very low quality evidence from 1 observational study (n=236) in NICU babies who received PN for a median of 2 days showed no clinically important difference in babies receiving PN with osmolarity > 900 mOsm/L versus PN with osmolarity ≤ 900 mOsm/L. However, there was uncertainty around the effect: RR 1.24 (95% CI 0.92, 1.67)
Rate of line related events per 100 patient days of PN (>37 weeks’ GA)
  • Very low quality evidence from 1 observational study (n=236) showed no clinically important difference in babies receiving PN with osmolarity > 900 mOsm/L versus PN with osmolarity ≤ 900 mOsm/L. However, there was uncertainty around the effect: RR 0.85 (95% CI 0.64, 1.13)

Economic evidence statements

No economic evidence was identified which was applicable to this review question.

The committee’s discussion of the evidence

Interpreting the evidence
The outcomes that matter most

The committee prioritised a number of critical outcomes including extravasation, bloodstream infections and thrombophlebitis. These outcomes were selected because they are clinically relevant adverse events which are directly associated with the concentration of the fluid given through a centrally and peripherally inserted catheter for PN in babies. Extravasation (leakage of fluid into the body), bloodstream infections and thrombophlebitis can all occur when the vein is weakened either by multiple insertion or by higher concentration of the fluid. No important outcomes were selected by the committee.

The quality of the evidence

The quality of evidence for this review was assessed using GRADE methodology. The evidence presented was considered very low quality indicating high uncertainty in the reliability of the data. This was due to very serious risks of bias associated with the selection of participants, classification of the interventions and the measurement of outcomes. The study was retrospective, it was unclear whether the start and follow-up of the intervention was the same for all participants, and the measurement of outcomes may have been minimally influenced due to knowledge of the intervention. The evidence was also considered very low quality due to serious and very serious imprecision, whereby the 95% confidence intervals crossed either one or both default minimally important differences (MIDs).

Benefits and harms

The committee discussed the evidence and noted that the pattern of results suggested that PN with an osmolarity greater than 900 mOsm/L could be given peripherally for a short duration without adverse events. However, they were concerned that this was based on only one study and that the evidence for all outcomes was assessed as very low quality according to GRADE criteria. Given their limited confidence in the evidence, the committee made the recommendations by informal consensus and based on their experience and expertise.

The committee agreed, based on their experience and expertise, that in general a central venous catheter should be used when giving PN. The committee discussed the risks and benefits associated with centrally and peripherally inserted catheters in clinical practice. They noted how the use of a centrally inserted catheter can reduce the number of peripheral cannulae inserted and hence the number of procedures the baby is exposed to and the number of skin punctures required. Serious potential complications such as central venous thrombosis and extravasation (including into the thoracic cavity and pericardium) are rare but must be considered with centrally inserted catheters, as they are not associated with peripheral catheters. Even though babies with central venous catheters are thought to be at greater risk of sepsis the committee agreed, based on their knowledge, that this risk would be outweighed by the greater risk of localised thrombosis and extravasation for peripheral administration. The committee also discussed the perspective of parents and acknowledged the possible increased distress due the potential to require multiple insertions of peripheral cannulae. The committee agreed, based on expertise that on balance the use of centrally inserted catheters would be the preferred option for clinical practice. Deviation from this would be on an individual risk/benefit basis which could be discussed with the baby’s parents.

The committee discussed the evidence presented which indicated that PN with an osmolarity greater than 900 mOsm/L could be given peripherally for a short duration without adverse events, and specifically up to 1425 mOsm/L (Cies 2014). Therefore, the use of peripherally inserted catheters could be considered for use with PN of higher osmolality or osmolarity. However, the committee agreed that it was not possible to recommend a specific safe concentration for parenteral nutrition delivered peripherally because of the wide range of concentrations used in the different groups in the study as well as the high uncertainty in the reliability of the data. Despite this the committee acknowledged that although severe extravasation injuries are rare with peripherally inserted catheters, the likelihood of these may be increased, depending on the osmolality and type of fluid infused. As a result, PN is not usually given peripherally in clinical practice when the osmolality or osmolarity is high and they decided to only recommend peripheral insertion in particular circumstances. Based on their knowledge of clinical practice, the committee noted that the insertion of central catheters requires more skill and starting PN may be delayed if the necessary expertise required for insertion is unavailable. Peripherally inserted catheters do not require the same level of expertise for insertion and can generally be inserted quicker than a central line, and so can be used for more immediate PN administration; therefore, if the use of a central venous catheter is likely to delay administration of PN, then peripheral venous access should be used. The committee did not define how long parenteral nutrition can be delayed before peripheral venous access should be considered, because this decision will be based on clinical judgement. Ideally, delays should not exceed the 8 hours specified in recommendation 1.1.6 (see the guideline document and evidence review A2), but healthcare professionals will need to consider the risks and benefits of inserting a peripheral line if it is anticipated that a central venous catheter would be inserted soon. To avoid repeated insertion of peripheral lines (due to their shorter life span) the committee also noted that it could be used for short term administration of PN or for a short time to avoid interruption (for instance if the expertise for a more complicated insertion is not immediately available) in the provision of PN.

Only if neither of the above options are possible, or there is a prolonged need for PN (for example in babies with a critical illness), then surgically inserted central catheters could be recommended, the committee agreed this by informal consensus and based on their clinical experience. This would be because only a small proportion of babies would require this, it would need to be carried out by a surgeon (which would cause delay) and being a more invasive procedure than non-surgically placed central catheters it would also be a riskier procedure for the baby.

Having identified the limitations of the evidence, the committee agreed that there is a need for further research in this area because of the risks associated with administering PN in babies through a centrally or peripherally inserted catheter. It is important to identify whether osmolality or osmolarity of PN can help guide whether it is safe to administer PN peripherally or centrally to avoid adverse events and to provide babies with optimum care. The committee therefore made a research recommendation by informal consensus to address this topic.

Cost effectiveness and resource use

No economic studies were identified which were applicable to this review question. This review was prioritised for economic modelling. However, clinical data was insufficient to inform the economic analysis.

The committee agreed that peripheral venous line insertion is cheap, quick and has a relatively low risk of sepsis when compared to central venous lines. However, the risk of localised thrombosis and extravasation are greater for peripheral administration which may require expensive management and result in detrimental impact on health related quality of life and a quality-adjusted life year (QALY) loss.

The committee further explained that a central venous catheter to administer PN is a relatively expensive procedure, requires expertise for insertion; and although rare can be associated with significant adverse events. However, the committee noted that in most babies the overall intervention costs are likely to be similar between a one-off central venous catheter insertion and multiple daily peripheral line placements since PN is generally given over a number of days. The committee further explained that since a baby may require peripheral venous reinsertion each day for PN and multiple extravasation injuries, which although mostly minor add to the handling and distress of the baby and family. This method creates multiple opportunities for infections that may require expensive NHS care. The committee also pointed out that peripheral line placement is painful and requires more frequent handling of babies which may have a detrimental impact on babies’ health-related quality of life and a QALY loss. Moreover, the committee also discussed the perspective of parents who would likely experience more distress due to the multiple insertion points associated with peripherally inserted catheters. Consequently the use of a central venous catheter may lead to the improvements not only in babies’ but also in parents’ health related quality of life and a QALY gain. Overall, given the above considerations and that the benefits outweighed the harms, the committee was of a view that generally a central venous catheter was potentially a more cost-effective approach for PN when compared with a peripheral venous administration for PN.

The committee further explained that in some instances the use of peripheral venous administration of PN is likely to represent a cost-effective use of NHS resources. Mainly, this is expected to be when the duration of PN is likely to be short or in cases where central venous access is unavailable and there is a potential for delays in starting PN. The committee explained that where the duration of PN is short the high cost associated with a central venous catheter insertion could be avoided. Also, the delays in PN can exacerbate problems which may require expensive NHS care.

Similarly, the committee agreed based on experience that surgically inserted central catheters could be considered to ensure positive outcomes for babies in whom central access is required but is not accessible through other means; or where long-term PN is anticipated. In this small proportion of babies a surgically inserted central catheter for PN would be deemed a cost effective approach.

The committee further explained that the recommendations in this area reflect practice across many units and as such the resource impact to the NHS, if any, is likely to be negligible.

References

  • Cies 2014

    Cies, Jeffrey J., Moore, Wayne S., 2nd, Neonatal and pediatric peripheral parenteral nutrition: what is a safe osmolarity? Nutrition in clinical practice: official publication of the American Society for Parenteral and Enteral Nutrition, 29, 118–24, 2014 [PubMed: 24336401]

Appendices

Appendix A. Review protocols

Review protocol for review question: What overall osmolality (concentration of calcium and glucose/dextrose), in parenteral nutrition can determine whether to administer centrally or peripherally?

Image

Table

Peripherally inserted catheters are an alternative option to central catheters, and are considered easier to insert and less expensive. However, administration of PN peripherally can result in complications such as thrombophlebitis due to high osmotic (more...)

Appendix B. Literature search strategies

Appendix C. Clinical evidence study selection

Clinical study selection for review question: What overall osmolality (concentration of calcium and glucose/dextrose), in parenteral nutrition can determine whether to administer centrally or peripherally?

Figure 1. PRISMA Flow chart of clinical article selection for review question on venous access for PN in preterm and term babies.

Appendix D. Clinical evidence tables

Clinical evidence table for review question: What overall osmolality (concentration of calcium and glucose/dextrose), in parenteral nutrition can determine whether to administer centrally or peripherally?

Table 3. Clinical evidence table for included studies (PDF, 376K)

Appendix E. Forest plots

Forest plots for review question: What overall osmolality (concentration of calcium and glucose/dextrose), in parenteral nutrition can determine whether to administer centrally or peripherally?

No meta-analysis was conducted for this review; therefore there are no forest plots.

Appendix F. GRADE tables

GRADE tables for review question: What overall osmolality (concentration of calcium and glucose/dextrose), in parenteral nutrition can determine whether to administer centrally or peripherally?

Table 4. Evidence profile for outcomes related to the comparison of PN with osmolarity > 900 mOsm/L versus PN with osmolarity ≤ 900 mOsm/L in babies receiving peripherally inserted catheters

Appendix G. Economic evidence study selection

Economic evidence study selection for review question: What overall osmolality (concentration of calcium and glucose/dextrose), in parenteral nutrition can determine whether to administer centrally or peripherally?

One global search was conducted for all review questions. See supplementary material D for further information.

Appendix H. Economic evidence tables

Economic evidence tables for review question: What overall osmolality (concentration of calcium and glucose/dextrose), in parenteral nutrition can determine whether to administer centrally or peripherally?

No evidence was identified which was applicable to this review question.

Appendix I. Health economic evidence profiles

Economic evidence profiles for review question: What overall osmolality (concentration of calcium and glucose/dextrose) in parenteral nutrition can determine whether to administer centrally or peripherally?

No evidence was identified which was applicable to this review question.

Appendix J. Health economic analysis

Economic analysis for review question: What overall osmolality (concentration of calcium and glucose/dextrose) in parenteral nutrition can determine whether to administer centrally or peripherally?

No economic analysis was conducted for this review question.

Appendix K. Excluded studies

Excluded studies for review question: What overall osmolality (concentration of calcium and glucose/dextrose), in parenteral nutrition can determine whether to administer centrally or peripherally?

Economic studies

No economic evidence was identified for this review. See supplementary material D for further information.

Appendix L. Research recommendations

Research recommendations for review question: What overall osmolality (concentration of calcium and glucose/dextrose) in parenteral nutrition can determine whether to administer centrally or peripherally?

Research recommendation

What overall osmolality (or concentration of calcium and glucose/dextrose) in parenteral nutrition can determine whether to administer centrally or peripherally?

Why this is important

Parenteral Nutrition (PN) is administered intravenously, and either peripheral or central venous lines can be used. Central lines are often inserted through the umbilical vessels in new-born infants, but can also be inserted peripherally; they are used for drug infusions as well as PN.

Central lines are positioned in a large bore central vein. This allows infusion of more concentrated substances securely; and in general these lines are able to be left in situ for a longer period of time if carefully maintained. However, they require a greater degree of technical skill for insertion; and can be more prone to serious complications such as being a source of late onset sepsis. Peripheral lines are very commonly used for a number of indications on neonatal units and are generally easier to insert. They have a shorter life span. As the infusions are running into a smaller peripheral vein, there is greater risk of the infusion causing direct damage to the vein (thrombophlebitis) or leaking out into the surrounding tissues (extravasation). This is particularly true where there is a higher concentration (as measured by osmolality or osmolarity depending on the unit of measurement) of the PN infusion fluid, such as a formulation with a higher dextrose load. It is therefore important to determine whether to administer PN centrally or peripherally.

Table 6. Research recommendation rationale

Table 7. Research recommendation modified PICO table